1-6 of 6
Viswanathan Ramakrishnan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, Martha D. Wellons, Heidi Sankala, Austin Doyle, John Wright, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1873–1883.
https://doi.org/10.1158/1078-0432.CCR-12-2926
Published: 02 April 2013
View article titled, A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Open the PDF for A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 in another window
Includes: Supplementary data
Journal Articles

Phase II Trials Powered to Detect Tumor Subtypes

John D. Roberts, Viswanathan Ramakrishnan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5538–5545.
https://doi.org/10.1158/1078-0432.CCR-10-2466
Published: 01 September 2011
View article titled, Phase II Trials Powered to Detect Tumor Subtypes
Open the PDF for Phase II Trials Powered to Detect Tumor Subtypes in another window
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Beata Holkova, E. Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader, Neha Talreja, Martha D. Wellons, Kevin T. Hogan, G. David Roodman, Domenico Coppola, Loveleen Kang, Jana Dawson, Robert K. Stuart, Cody Peer, William D. Figg, Sr., Sarah Kolla, Austin Doyle, John Wright, Daniel M. Sullivan, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3388–3397.
https://doi.org/10.1158/1078-0432.CCR-10-2876
Published: 15 May 2011
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

John D. Roberts, Mitchell R. Smith, Eric J. Feldman, Louise Cragg, Michael M. Millenson, Gail J. Roboz, Connie Honeycutt, Rose Thune, Kristin Padavic-Shaller, W. Hans Carter, Viswanathan Ramakrishnan, Anthony J. Murgo, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5809–5816.
https://doi.org/10.1158/1078-0432.CCR-05-2730
Published: 04 October 2006
View article titled, Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma
Open the PDF for Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma in another window
Journal Articles

Melanoma Differentiation-associated 7 (Interleukin 24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells in Vitro and in Vivo

Adly Yacoub, Clint Mitchell, Andrea Lister, Irina V. Lebedeva, Devanand Sarkar, Zao-Zhong Su, Carter Sigmon, Robert McKinstry, Viswanathan Ramakrishnan, Liang Qiao, William C. Broaddus, Rahul V. Gopalkrishnan, Steven Grant, Paul B. Fisher, Paul Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3272–3281.
Published: 05 September 2003
View article titled, Melanoma Differentiation-associated 7 (Interleukin 24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells <em>in Vitro</em> and <em>in Vivo</em>
Open the PDF for Melanoma Differentiation-associated 7 (Interleukin 24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells <em>in Vitro</em> and <em>in Vivo</em> in another window